Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

Medtronic has announced the SMART trial’s two-year outcomes of Evolut TAVR for aortic stenosis (AS) and small aortic annulus.

At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.

Highlights,Evolut TAVR demonstrated significantly lower rates of bioprosthetic valve dysfunction (BVD) compared to SAPIEN at ...

Medtronic plc released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli. The SMall Annuli Randomized To Evolut or ...

Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...

Per the latest update, the Evolut FX+ TAVR system is seeing strong uptake in the United States, with international expansion progressing well. With favorable trial results, Medtronic’s ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMa ...

(RTTNews) - Medtronic plc (MDT ... as measured by bioprosthetic valve dysfunction (BVD) at two years for Evolut TAVR compared to SAPIEN. The SMART two-year data demonstrated that Evolut TAVR ...